CMTC and prediction in pCR of neoadjuvant chemotherapy. (A) The percentage of pCR between non-Her2+/TN tumors (non-H+/TN) and Her2+/TN tumors (H+/TN) and within the three CMTC groups of the 248 breast cancers with neoadjuvant chemotherapy. (B) Comparison of area under the curve (AUC) to predict pCR in CMTC-3 tumors (CMTC-3 vs CMTC-1 and CMTC-2; P = 0.0001), Her2+/TN tumors (Her2+/TN vs non-Her2+/TN; P = 0.0001), Her2+ tumors (Her2+ vs Her2-; P = 0.0245) and TN tumors (TN vs non-TN; P = 0.0052). By comparing the gene profiles of individual tumors with CMTC-3, a correlation coefficient (r) was calculated as an index reflecting its degree of similarity to the expression pattern of CMTC-3 tumors. The two graphs show the relationship between r value and pCR (C) in the 111 Her2+/TN cancers and (D) in all 248 cancers. pCR status (deep pink), Her2+ status (deep pink) and TN status (dark blue), respectively, are indicated by the bottom bars. AUC = area under the curve; CMTC = ClinicoMolecular Triad Classification; Her2 = human epidermal growth factor receptor 2; pCR = pathological response; TN = triple-negative.